Earnings summaries and quarterly performance for Y-mAbs Therapeutics.
Executive leadership at Y-mAbs Therapeutics.
Michael Rossi
President and Chief Executive Officer
Thomas Gad
Chief Business Officer
Doug Gentilcore
Senior Vice President and DANYELZA Business Unit Head
John LaRocca
Senior Vice President, General Counsel and Secretary
Joris Wiel Jan Wilms
Senior Vice President and Chief Operating Officer
Peter Pfreundschuh
Executive Vice President, Chief Financial Officer and Treasurer
Board of directors at Y-mAbs Therapeutics.
Research analysts who have asked questions during Y-mAbs Therapeutics earnings calls.
Alec Stranahan
Bank of America
4 questions for YMAB
Justin Walsh
Jones Trading
4 questions for YMAB
Nicole Germino
Truist Securities
4 questions for YMAB
Jeff Jones
Oppenheimer & Co. Inc.
3 questions for YMAB
Li Wang Watsek
Cantor Fitzgerald
3 questions for YMAB
Michael Ulz
Morgan Stanley
3 questions for YMAB
Brian Kemp Dolliver
Brookline Capital Markets, LLC
2 questions for YMAB
David Nierengarten
Wedbush Securities
2 questions for YMAB
Etzer Darout
BMO Capital Markets
2 questions for YMAB
John Newman
Canaccord Genuity Group Inc.
2 questions for YMAB
William Maughan
Clear Street LLC
2 questions for YMAB
Chiara Montironi
Kempen & Co
1 question for YMAB
Justin Wolf
Jones Trading
1 question for YMAB
Mike Ulz
Morgan Stanley
1 question for YMAB
Robert Burns
H.C. Wainwright & Co.
1 question for YMAB
Recent press releases and 8-K filings for YMAB.
- Y-mAbs Therapeutics, Inc. (YMAB) completed its merger with Yosemite Merger Sub, Inc., a wholly-owned subsidiary of Perseus BidCo US, Inc., on September 16, 2025, resulting in YMAB becoming a wholly-owned subsidiary of Perseus BidCo US, Inc..
- The acquisition was finalized through a cash tender offer at $8.60 per Share, with approximately 39,827,138 Shares tendered, representing 87.22% of outstanding shares. The aggregate consideration paid for the Offer and Merger was approximately $413 million.
- Effective September 16, 2025, YMAB's shares were delisted from the Nasdaq Global Select Market, and the company intends to deregister its shares and suspend reporting obligations.
- Following the merger, the entire Board of Directors and several key officers resigned, and new directors and officers were appointed from the acquiring entity.
Quarterly earnings call transcripts for Y-mAbs Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more